These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9895438)

  • 21. Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA.
    Coli L; Cianciolo G; Feliciangeli G; De Sanctis LB; Zanchelli F; Dalmastri V; De Pascalis A; Sestigiani E; Donati G; Stefoni S
    Contrib Nephrol; 1999; 125():111-9. PubMed ID: 9895435
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis.
    Opatrný K; Krouzecký A; Wirth J; Vít L; Eiselt J
    Artif Organs; 1998 Oct; 22(10):816-20. PubMed ID: 9790077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydraulic and flow dynamic characteristics of PMMA dialyzers.
    Brendolan A; Ronco C; Ghezzi PM; Scabardi M; La Greca G
    Contrib Nephrol; 1999; 125():41-52. PubMed ID: 9895429
    [No Abstract]   [Full Text] [Related]  

  • 24. Vitamin E-bonded cellulose membrane, lipoperoxidation, and anemia in hemodialysis patients.
    Triolo L; Malaguti M; Ansali F; Comunian MC; Arcangeloni O; Coppolino F; Marrocco F; Sicoli R; Biagini M
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):185-91. PubMed ID: 12751839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent findings on the pathogenesis and therapy of anemia in chronic kidney failure].
    Moccia F; Morra L; Gurreri G
    Recenti Prog Med; 1992 Oct; 83(10):572-6. PubMed ID: 1462041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hematologic changes in chronic uremia].
    Schnurr E
    Dtsch Med Wochenschr; 1979 Nov; 104(47):1678-82. PubMed ID: 510197
    [No Abstract]   [Full Text] [Related]  

  • 28. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new polymethylmethacrylate membrane for hemodialysis.
    Bonomini M; Fiederling B; Bucciarelli T; Manfrini V; Di Ilio C; Albertazzi A
    Int J Artif Organs; 1996 Apr; 19(4):232-9. PubMed ID: 8786174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels.
    Tessitore N; Lapolla A; Aricò NC; Poli A; Gammaro L; Bassi A; Bedogna V; Corgnati A; Reitano R; Fedele D; Lupo A
    J Nephrol; 2004; 17(5):707-14. PubMed ID: 15593039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adequate dialysis].
    Maduell Canals F
    Nefrologia; 2002; 22(2):111-34. PubMed ID: 12085413
    [No Abstract]   [Full Text] [Related]  

  • 32. Dialysate calcium concentration ofKyriazis J; Glotsos J
    Nephron; 2000 Jan; 84(1):85-6. PubMed ID: 10644916
    [No Abstract]   [Full Text] [Related]  

  • 33. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 35. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 36. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
    Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
    Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
    Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
    Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
    Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
    [No Abstract]   [Full Text] [Related]  

  • 39. Choice of modality with the use of high-performance membrane and evaluation for clinical effects.
    Masakane I
    Contrib Nephrol; 2011; 173():84-94. PubMed ID: 21865780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodialysis membrane biocompatibility--does it matter?
    Jacobson SH
    Scand J Urol Nephrol; 1999 Apr; 33(2):83-8. PubMed ID: 10360446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.